Evaxion Completes One-Year Extension of Phase 2 Trial for Personalized Melanoma Vaccine EVX-01

On April 7, 2026, Evaxion A/S announced the completion of the last patient visit in the one-year extension of its Phase 2 clinical trial for EVX-01, a personalized cancer vaccine for advanced melanoma. EVX-01 is designed using the company's proprietary AI-Immunology™ platform. During the first two years of the trial, patients received EVX-01 in combination with Merck’s Keytruda, while the third-year extension evaluated EVX-01 as a monotherapy. The trial has previously reported encouraging results, including a 75% Objective Response Rate (ORR), with 12 out of 16 patients responding and four achieving a complete response. Notably, 92% of patients remained responsive at the two-year follow-up with no observed relapses. The vaccine also demonstrated high immunogenicity, inducing T-cell responses in 81% of targeted neoantigens. The company plans to analyze the three-year clinical efficacy data to evaluate the durability of the immune response and the vaccine's effect as a standalone treatment. Full data presentation is expected in the second half of 2026.